In the year 2021, there were three new Food and Drug Administration approvals for all
leukemia types: asciminib (Scemblix) for chronic myeloid leukemia, brexucabtagene …

The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax
(Ven), a BCL-2–selective inhibitor, combined with hypomethylating agents (HMA) such as …

Venetoclax with azacitidine is the standard of care for patients with AML who are unfit for
intensive chemotherapy, however uncertainties remain regarding the treatment schedule …

Malignancy can arise in many forms in the hematopoietic system, affecting both lymphoid
and myeloid cells and causing acute and chronic disorders and affecting all age groups …

Sprouty-related, EVH1 domain-containing protein 1 (SPRED1) has been identified as a
novel tumor suppressor gene in acute myeloid leukemia (AML). Previous studies showed …

Background Therapies for relapsed/refractory acute myeloid leukemia remain limited and
outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or …

Department of Hematology, Nippon Medical School, Tokyo, Japan Acute myeloid leukemia
(AML) is a heterogeneous hematopoietic malignancy accompanied by impaired …

Since the early 1970s, the treatment of acute myeloid leukaemia (AML) has undergone a
major transformation. Initially based on only two drugs, an anthracycline and cytosine …

摘要目的: 分析急性髓系白血病(AML) 患者血小板输注疗效不佳及短期死亡的危险因素. 方法:
将2019 年4 月至2021 年1 月期间南部战区总医院收治的97 例AML 患者作为研究对象 …

The American Society of Hematology (ASH) 2020 guidelines for treating newly diagnosed
acute myeloid leukemia (AML) in older adults answered 6 critical treatment questions …